Financial Performance - The net profit attributable to the parent company's shareholders for 2022 is CNY 115,681,544.43, with a total distributable profit of CNY 217,201,772.33 as of December 31, 2022[5]. - The proposed cash dividend is CNY 0.90 per 10 shares (including tax), totaling CNY 12,240,000.00, which represents 10.58% of the net profit attributable to the parent company[5]. - The company's operating revenue for 2022 was CNY 322,359,785.92, a decrease of 34.18% compared to CNY 489,755,358.90 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 115,681,544.43, down 1.65% from CNY 117,618,137.99 in 2021[25]. - The cash flow from operating activities showed a net outflow of CNY -37,261,950.98 in 2022, a decline of 169.22% compared to CNY 53,827,755.74 in 2021[25]. - The basic earnings per share for 2022 was CNY 0.85, a decrease of 1.16% from CNY 0.86 in 2021[27]. - The total assets at the end of 2022 were CNY 1,198,844,121.40, an increase of 6.13% from CNY 1,129,566,326.94 at the end of 2021[26]. - The company reported a decrease in the weighted average return on equity to 12.11% in 2022 from 13.64% in 2021, a reduction of 1.53 percentage points[27]. - The net profit after deducting non-recurring gains and losses was CNY 96,730,991.02, down 10.31% from CNY 107,847,786.04 in 2021[25]. - The total net assets attributable to shareholders increased to CNY 1,004,966,459.25 at the end of 2022, up 11.47% from CNY 901,524,914.82 at the end of 2021[25]. Business Operations and Strategy - The company experienced a significant decline in revenue due to external factors affecting the supply-demand relationship in the industry[27]. - The company secured a CNY 69 million contract for the "Zhongxiang Smart Medical Integrated Project," expanding its "To-G" bulk model business[36]. - The company established joint ventures in various fields, including unmanned medicine dispensing machines and automated logistics, indicating a strategic expansion into new business areas[37]. - A joint venture was signed with Ajlan & Bros Information Technology Company to establish a new company in Riyadh, Saudi Arabia, aiming to enhance the company's presence in the Middle East and North Africa markets[38]. - The company focused on improving operational capabilities and management efficiency, implementing strict budget controls and lean production management[39]. - The company is actively pursuing opportunities in the smart pharmaceutical management sector, driven by increasing demands for efficiency and quality in drug dispensing[44]. - The establishment of centralized intravenous medication preparation centers is creating further development space for high-tech automation in the pharmaceutical management field[45]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[55]. - The company’s projects involve a comprehensive approach including hardware and software integration, system design, and ongoing maintenance services[57]. Market Trends and Growth Potential - The global market for automated pharmacy systems is growing, with the average adoption rate in developed countries around 30% as of 2013[43]. - In the U.S., 97% of hospitals were equipped with automated dispensing devices by the end of 2014, highlighting the trend towards automation in healthcare[43]. - The market for retail pharmacies is expected to grow due to the rise of internet healthcare and automation, with a focus on O2O models[48]. - The company is focusing on expanding its market presence in Hubei and surrounding provinces, leveraging synergies with its existing products[110]. - The market penetration rate of automated pharmacy equipment in China is expected to increase significantly due to rising healthcare investments and policy support, with a projected growth in the industry[111]. - By 2023, the penetration rates for automated pharmacy equipment in various cities are forecasted to rise: Beijing from 4% to 45%, Shenzhen from 6% to 57%, Suzhou from 30% to 65%, and Shanghai from 5% to 48%[112]. Research and Development - The total R&D expenditure amounted to CNY 22,415,836.21, representing 6.95% of operating income[85]. - The company has 70 R&D personnel, accounting for 19.23% of the total workforce[86]. - The company aims to enhance its R&D capabilities and product development, focusing on market-oriented strategies and leveraging technologies like machine vision and deep learning[116]. - A talent development plan will be implemented to strengthen the R&D team and attract experienced professionals to support the company's growth[121]. Governance and Compliance - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[3]. - The audit report issued by the accounting firm is a standard unqualified opinion[4]. - The internal control system was evaluated as effective, with no significant deficiencies found in financial reporting controls[165]. - The company has established specialized committees under the board, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee[147]. - The company has no reported penalties from securities regulatory agencies in the past three years[145]. - The company has maintained a stable leadership structure, with key executives serving since 2017, ensuring continuity in management and strategic direction[137]. Shareholder Relations and Commitments - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with a lock-up extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[180]. - The company has reiterated its commitment to adhere to all relevant laws and regulations regarding shareholding and transfer practices[178]. - The company will ensure compliance with all relevant laws and regulations regarding share repurchase and management[187]. - Major shareholders, including the controlling shareholders, have committed to fulfilling all obligations related to public commitments made during the IPO process[190]. - The company guarantees that the prospectus for the IPO does not contain false records or misleading statements, and it will bear legal responsibility for its accuracy[193].

Financial Performance - The company's operating revenue for Q1 2023 was ¥61,275,234.89, representing a year-on-year increase of 35.03%[5] - The net profit attributable to shareholders for the same period was ¥9,943,347.23, reflecting a growth of 40.98% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.07, an increase of 40.00% year-on-year[6] - The weighted average return on equity rose to 0.98%, an increase of 0.20 percentage points from the previous year[6] - The company reported a significant increase in sales revenue from services, contributing to the overall revenue growth[23] - The financial outlook remains positive, with expectations for continued revenue growth and improved profitability in the upcoming quarters[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,198,379,220.88, showing a slight decrease of 0.04% compared to the end of the previous year[6] - As of March 31, 2023, the total assets of the company amounted to CNY 1,198,379,220.88, slightly down from CNY 1,198,844,121.40 at the end of 2022[17] - The company's current assets totaled CNY 776,059,761.70, a decrease from CNY 829,966,363.51 at the end of 2022, indicating a decline of approximately 6.5%[18] - The company's non-current assets increased to CNY 422,319,459.18 from CNY 368,877,757.89, reflecting an increase of about 14.4%[18] - The total liabilities of the company were CNY 106,860,248.96, down from CNY 115,583,848.53, representing a decrease of approximately 7.4%[19] - The company's cash and cash equivalents were CNY 303,158,377.31, down from CNY 366,273,999.90, indicating a decline of about 17.2%[17] Cash Flow - The net cash flow from operating activities was negative at -¥46,915,420.31, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥46,915,420.31, an improvement from a net outflow of ¥60,500,250.05 in Q1 2022[27] - The net cash flow from investing activities was -$40,960,093.79, an improvement from -$47,339,470.31 in the previous period[28] - The net cash flow from financing activities was $24,735,729.17, with cash inflow from borrowings amounting to $25,000,000.00[28] - The total cash and cash equivalents at the end of the period decreased to $270,988,348.82 from $360,524,063.75, reflecting a net decrease of $63,115,622.59[28] Expenses - The company reported a 75.28% increase in operating costs, which aligned with the revenue growth during the period[11] - Operating costs amounted to ¥51,831,889.26, up from ¥34,700,305.33, reflecting a significant increase in expenses[23] - Research and development expenses were ¥5,567,972.60, slightly down from ¥5,569,046.07 in the previous year[24] Receivables and Inventory - The company experienced a 68.21% increase in other receivables, attributed to an increase in land deposit guarantees[10] - The company's inventory increased to CNY 91,289,460.26 from CNY 74,023,447.28, reflecting an increase of about 23.4%[18] - Accounts receivable decreased to CNY 301,081,720.73 from CNY 332,887,498.88, a reduction of approximately 9.5%[18] - The company’s other receivables increased to CNY 18,214,695.02 from CNY 10,828,485.10, an increase of approximately 68.5%[18] Borrowings - Short-term borrowings increased by 100.00% during the reporting period, indicating a rise in bank short-term loans[11] - The company reported a decrease in short-term borrowings to CNY 25,000,000.00, indicating a reduction in leverage[19] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[28]

Group 1: Company Performance and Recovery - The company resumed full operations on June 1, 2022, after being approved as a second batch of companies for resumption in Shanghai [3] - The overall business performance remained stable despite the impact of the COVID-19 pandemic [3] - The company has implemented refined management strategies to adapt to the pandemic situation [4] Group 2: Market Position and Client Base - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, with more than half of the top 100 hospitals in China as clients [3] - The company focuses on the pharmaceutical intelligent management sector and has a strong market presence in economically developed coastal regions, particularly in first and second-tier cities [4] Group 3: Future Strategy and Business Development - In 2022, the company aims to enhance product development and market expansion while optimizing production and management efficiency [4] - The company plans to explore the "to-G" market and increase its market share in the retail pharmaceutical sector [4] - The company has a strategic layout for the retail market and aims to penetrate lower-tier medical service institutions [4]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,885,617.06, representing a 6.74% increase compared to ¥151,665,389.91 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥54,360,227.05, up 5.02% from ¥51,762,534.45 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥51,610,072.47, which is an increase of 11.20% compared to ¥46,411,777.07 in the same period last year[20]. - The basic earnings per share was CNY 0.40, up 5.26% from CNY 0.38 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.40, reflecting a 5.26% increase year-on-year[21]. - The weighted average return on equity was 5.85%, down 0.32 percentage points from the previous year[21]. - The weighted average return on assets after deducting non-recurring gains and losses increased by 0.03 percentage points to 5.56%[21]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[97]. - The company recorded a comprehensive income of CNY 54,360,227.05 for the first half of 2022, indicating positive performance in its financial results[171]. Cash Flow and Assets - The net cash flow from operating activities decreased by 65.81%, amounting to ¥9,395,849.83, down from ¥27,478,194.54 in the previous year[20]. - The company's cash and cash equivalents decreased by 11.57% to 414.65 million yuan compared to the previous year[63]. - The company's inventory decreased by 20.90% to 48.03 million yuan compared to the previous year[63]. - The total current assets decreased to ¥799,579,832.93 from ¥850,687,666.75, reflecting a decline of approximately 6%[148]. - Cash and cash equivalents decreased to ¥414,646,712.82 from ¥468,916,999.82, a reduction of about 11.5%[148]. - The company reported a net decrease in cash and cash equivalents of CNY -56,488,152.25, an improvement from CNY -234,215,319.20 in the prior year[167]. Business Operations and Strategy - The company faced challenges due to the COVID-19 pandemic, affecting project timelines and operational cash flow[21]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[41]. - The company aims to strengthen its market position as public hospitals' roles are expected to be reinforced by government policies[35]. - The retail pharmacy market share is anticipated to increase due to the rapid development of internet healthcare and automation in drug management[35]. - The company is focusing on building an industrial ecosystem and expanding into related business areas, including automation in wards and operating rooms[56]. Research and Development - Research and development expenses amounted to 10.38 million yuan, representing a growth of 5.72% compared to the previous year[57]. - The company has established a comprehensive R&D system with nearly 20 years of experience in intelligent drug management, enhancing its innovation capabilities[45]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving operational efficiency and product quality[103]. Shareholder Commitments and Governance - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with an automatic extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[104]. - Major shareholders, including Ningbo Hydra, have pledged to hold 1,020,000 shares without transfer or management delegation for 36 months post-IPO[105]. - The controlling shareholder, Dai Jianwei, plans to support the company's development and will not reduce shareholdings below the IPO price for two years post-lock-up, with annual reductions capped at 25% of their holdings[107]. - The company will implement stock price stabilization measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days within three years post-IPO[109]. - The company guarantees that the prospectus for the IPO does not contain false statements or omissions, and will compensate investors for losses if such issues are identified[117]. Market Position and Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[101]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and increase market penetration[102]. - The company has provided intelligent drug management projects for over 700 medical institutions, including top hospitals in China[36]. Financial Health and Liabilities - Total liabilities decreased to ¥94,769,032.15 from ¥154,027,955.51, a significant reduction of about 38.5%[150]. - The company reported a significant reduction in tax payables by 51.60% to CNY 17.24 million, attributed to early payments of VAT and corporate income tax[65]. - The company's accounts payable decreased by 59.72% to CNY 13.09 million, mainly due to the settlement of large project payments[65]. Compliance and Legal Matters - The company has not engaged in any significant litigation or arbitration matters during the reporting period[126]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[126]. - The company has not faced any penalties or corrective actions related to legal violations during the reporting period[126].

Financial Performance - The net profit attributable to the parent company's shareholders for 2021 was CNY 117,618,137.99, with a proposed cash dividend of CNY 0.9 per 10 shares, totaling CNY 12,240,000.00, which represents 10.41% of the net profit[5]. - The company's operating revenue for 2021 was CNY 489,755,358.90, representing a 70.76% increase compared to CNY 286,806,988.65 in 2020[21]. - Net profit attributable to shareholders for 2021 was CNY 117,618,137.99, a 22.85% increase from CNY 95,739,268.21 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 107,847,786.04, up 22.28% from CNY 88,194,212.79 in 2020[21]. - The company's total assets increased by 13.25% to CNY 1,129,566,326.94 at the end of 2021, compared to CNY 997,404,072.75 at the end of 2020[21]. - The weighted average return on equity decreased to 13.64% in 2021 from 29.01% in 2020, a decline of 15.37 percentage points[22]. - The basic earnings per share for 2021 was CNY 0.86, a decrease of 8.51% from CNY 0.94 in 2020[22]. - The company reported a net asset attributable to shareholders of CNY 901,524,914.82 at the end of 2021, a 10.87% increase from CNY 813,146,776.83 at the end of 2020[21]. Dividends and Profit Distribution - The company plans to maintain the total distribution amount unchanged, adjusting the per-share distribution ratio if there are changes in the total share capital before the dividend record date[5]. - The company has not proposed any capital reserve fund transfers to increase share capital or bonus shares for this profit distribution[5]. - The company plans to distribute a cash dividend of 0.9 yuan per 10 shares, totaling 12,240,000 yuan, which represents 10.41% of the net profit attributable to shareholders[160]. - The cash dividend policy aims to protect minority shareholders' rights and is based on the company's strategic management goals[159]. Risks and Compliance - The company has not disclosed any significant risks that could affect its future development in the report[8]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for providing guarantees[8]. - The company has not faced any penalties from securities regulatory authorities in the past three years[142]. - The company has no reported risks or dissenting opinions from the supervisory board during the reporting period[153]. Research and Development - Research and development expenses amounted to 23.20 million yuan, reflecting a growth of 41.93% year-on-year[32]. - The total R&D investment for the period is CNY 23,197,509.95, representing 4.74% of the operating revenue[85]. - The number of R&D personnel is 64, making up 19.63% of the total workforce[86]. - The company emphasizes the importance of R&D for maintaining competitive advantage in the pharmaceutical automation sector[54]. Market Expansion and Strategy - The company is actively expanding its market presence in central and western regions of China, targeting lower-tier medical institutions[36]. - The company aims to optimize its sales strategy and expand its distribution network, focusing on the growing market opportunities in China's healthcare infrastructure, particularly in second and third-tier cities[112]. - The company plans to capture a larger share of the retail pharmacy market by collaborating with leading clients and developing targeted products for the retail environment, enhancing brand penetration and overall revenue[113]. - The company is committed to expanding its dealer and agent network to strengthen its leading position in the domestic intelligent pharmaceutical management sector[110]. Governance and Management - The company has established four specialized committees under the board to ensure scientific and standardized decision-making[128]. - The company strictly adhered to legal regulations and internal control systems to maintain governance standards and protect shareholder rights[129]. - The company has a performance assessment system in place to align the interests of senior management with the company's long-term development[129]. - The company has maintained independence from its controlling shareholders in terms of personnel, assets, finance, and operations[129]. - The company has a structured remuneration decision-making process involving the compensation and assessment committee of the board[140]. Operational Performance - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, enhancing its brand advantage[64]. - The company successfully secured a large order for mobile medical service vehicles from the Hubei Provincial Health Commission, contributing significantly to revenue growth[23]. - The company experienced a significant increase in maintenance and service revenue due to business expansion[23]. - The company has a well-established after-sales service network covering major cities, ensuring rapid response to customer needs[66]. Inventory and Accounts Receivable - Inventory increased to 60.72 million yuan, a significant rise of 146.57% from the beginning of the period[31]. - Accounts receivable increased by 38.52% to ¥286,994,522.69, up from ¥207,185,026.24 in the previous period, primarily due to the impact of COVID-19 on medical institutions and pharmaceutical distribution companies[91]. - The company's inventory value at the end of the reporting period was 60.72 million yuan, which constitutes 7.14% of current assets, posing risks related to acceptance and impairment of inventory[122]. Shareholder Commitments and Lock-up Period - The company commits to a maximum of 25% share transfer annually after the lock-up period ends, and no transfers will occur within six months post-departure[188]. - The company will adhere to regulations regarding shareholding changes and lock-up periods as per relevant laws and regulations[182]. - The company’s major shareholders include Hanyu Pharmaceutical and Jianqu Investment, which also committed to similar lock-up agreements[186]. - The company will ensure that any share reduction attempts post-lock-up will not be below the IPO price adjusted for any corporate actions[185]. Social Responsibility - The company donated a total of 100,000 yuan to support poverty alleviation efforts in targeted regions, contributing to rural revitalization[176]. - The company implemented measures to ensure the normal operation of its products in hospitals during the pandemic, enhancing safety with contactless self-service medication dispensing devices[172].

Financial Performance - The company's operating revenue for Q1 2022 was ¥45,380,407.33, representing an increase of 11.19% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2022 was ¥7,052,836.21, reflecting a growth of 10.65% year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,012,578.93, which is an increase of 15.54% compared to the previous year[5]. - Total operating revenue for Q1 2022 was CNY 45,380,407.33, an increase of 11.5% compared to CNY 40,811,846.52 in Q1 2021[20]. - Net profit for Q1 2022 reached CNY 8,151,632.47, up 10.4% from CNY 7,378,978.29 in Q1 2021[21]. - Total operating costs for Q1 2022 were CNY 34,700,305.33, an increase of 10.4% from CNY 31,247,677.80 in Q1 2021[20]. Cash Flow and Assets - The company's cash flow from operating activities for Q1 2022 was negative at -¥60,500,250.05, indicating a significant cash outflow[5]. - Cash flow from operating activities showed a net outflow of CNY 60,500,250.05, worsening from a net outflow of CNY 51,838,262.91 in Q1 2021[25]. - Cash inflow from investment activities was CNY 50,044,046.16, while cash outflow was CNY 97,383,516.47, resulting in a net cash outflow of CNY 47,339,470.31[25]. - The total assets at the end of Q1 2022 were ¥1,064,942,116.69, a decrease of 5.72% from the end of the previous year[6]. - As of March 31, 2022, the company's total assets amounted to ¥1,064,942,116.69, a decrease from ¥1,129,566,326.94 as of December 31, 2021, reflecting a decline of approximately 5.7%[17]. - The company's current assets totaled ¥753,502,166.74, down from ¥850,687,666.75, indicating a decrease of about 11.4%[18]. - Cash and cash equivalents were reported at ¥361,024,063.75, a decrease of 23.0% from ¥468,916,999.82 at the end of 2021[17]. - The net increase in cash and cash equivalents for the period was -$107,892,936.07[26]. - The beginning balance of cash and cash equivalents was $468,416,999.82[26]. - The ending balance of cash and cash equivalents was $360,524,063.75[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,182[13]. - The largest shareholder, Dai Jianwei, holds 42.00% of the shares, totaling 57,113,219 shares[13]. Liabilities and Equity - The company's total liabilities were ¥81,272,014.66, down from ¥154,027,955.51, showing a significant reduction of about 47.3%[19]. - The equity attributable to shareholders increased slightly to ¥908,670,101.03 from ¥905,538,000.00, reflecting a marginal growth of 0.2%[19]. - The company reported a decrease in accounts payable from ¥32,498,762.59 to ¥12,428,953.12, a reduction of about 61.8%[19]. Research and Development - Research and development expenses increased by 31.45% during the reporting period, indicating a focus on innovation[11]. - Research and development expenses increased to CNY 5,569,046.07, representing a rise of 31.5% from CNY 4,236,733.51 in the previous year[20]. - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[16]. Future Outlook - Future outlook includes potential market expansion strategies, although detailed projections were not provided in the current report[16]. Other Financial Metrics - The basic earnings per share for Q1 2022 was ¥0.05, unchanged from the previous year[6]. - Basic and diluted earnings per share remained stable at CNY 0.05 for both Q1 2022 and Q1 2021[22]. - The company reported a significant increase in cash received from sales, totaling CNY 58,036,517.48, compared to CNY 32,586,433.49 in the same period last year[24]. - The company experienced a credit impairment loss of CNY -2,524,893.79, worsening from CNY -1,388,038.97 in Q1 2021[21]. - The impact of exchange rate changes on cash and cash equivalents was -$53,215.71[26].

Financial Performance - The company's operating revenue for Q3 2021 was ¥133,371,277.49, representing a year-on-year increase of 155.77%[5] - The net profit attributable to shareholders for Q3 2021 was ¥26,049,161.53, up 58.80% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥26,019,969.90, an increase of 89.29% year-on-year[5] - For the first three quarters of 2021, the total operating revenue reached ¥285,036,667.40, reflecting a growth of 60.35% compared to the same period last year[5] - The net profit attributable to shareholders for the first three quarters of 2021 was ¥77,811,695.98, which is a 31.79% increase year-on-year[5] - Operating profit for the first three quarters of 2021 was ¥91,338,382.34, compared to ¥75,545,868.75 in 2020, indicating an increase of about 20.9%[21] - Net profit attributable to shareholders of the parent company for the first three quarters of 2021 was ¥77,811,695.98, up from ¥59,040,696.18 in 2020, reflecting a growth of approximately 31.7%[22] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.19, an increase of 18.75% compared to the previous quarter[6] - The diluted earnings per share for Q3 2021 was also ¥0.19, reflecting the same growth rate of 18.75%[6] - The basic earnings per share for the first three quarters of 2021 was ¥0.57, slightly down from ¥0.58 in the same period of 2020[22] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,071,861,212.13, representing a 7.47% increase from the end of the previous year[6] - The equity attributable to shareholders at the end of Q3 2021 was ¥861,718,472.81, which is a 5.97% increase compared to the end of the previous year[6] - Current assets totaled RMB 824,013,504.61, slightly up from RMB 822,220,361.70 year-over-year[16] - Non-current assets increased to RMB 247,847,707.52 from RMB 175,183,711.05, representing a growth of approximately 41.4%[17] - Total liabilities reached RMB 142,896,849.50, compared to RMB 119,788,274.83 in the previous year, indicating an increase of about 19.3%[17] - The total assets of the company amounted to ¥1,071,861,212.13, an increase from ¥997,404,072.75 in the previous year, indicating a growth of about 7.4%[18] - The company's total equity reached ¥928,964,362.63, up from ¥877,615,797.92, reflecting an increase of approximately 5.8%[18] Cash Flow - The company reported a net cash flow from operating activities of ¥21,149,578.87 for the first three quarters of 2021, compared to ¥18,138,567.14 in the same period of 2020, showing an increase of about 11.1%[24] - The net cash flow from investing activities was -$182.35 million, compared to -$43.44 million in the previous period[25] - The total cash outflow from investing activities amounted to $302.74 million, with $250 million specifically for investment payments[25] - The net cash flow from financing activities was -$35.63 million, with cash inflow from borrowings at $33.72 million[25] - The company distributed dividends and interest payments totaling $27.82 million[25] - The net increase in cash and cash equivalents was -$197.03 million, contrasting with an increase of $8.49 million in the previous period[25] - The ending balance of cash and cash equivalents stood at $362.85 million, down from $559.88 million at the beginning of the period[25] Research and Development - Research and development expenses for the first three quarters of 2021 totaled ¥16,082,970.74, compared to ¥10,283,807.81 in 2020, marking a rise of approximately 56.5%[21] Other Information - The company has not reported any new product launches or technological advancements during this quarter[14] - There are no significant mergers or acquisitions reported in the current quarter[14] - The company did not apply the new leasing standards starting from 2021[25]

Financial Performance - The company achieved operating revenue of CNY 151,665,389.91, representing a 20.74% increase compared to the same period last year[19]. - The net profit attributable to shareholders reached CNY 51,762,534.45, up 21.40% year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,411,777.07, reflecting a 24.62% increase from the previous year[19]. - The net cash flow from operating activities was CNY 27,478,194.54, a decrease of 3.83% compared to the same period last year[19]. - The company's net assets attributable to shareholders increased to CNY 864,909,311.28, a growth of 6.37% from the end of the previous year[19]. - Total assets reached CNY 1,037,013,220.92, marking a 3.97% increase compared to the end of the previous year[19]. - Basic earnings per share decreased to CNY 0.38, down 9.52% from the same period last year[20]. - The weighted average return on net assets was 6.17%, a decrease of 7.75 percentage points year-on-year[20]. - The growth in performance for the first half of 2021 was primarily driven by an increase in operating profit[20]. - The total comprehensive income for the first half of 2021 was CNY 56,231,259.81, compared to CNY 46,473,321.24 in the previous year, reflecting a growth of approximately 20.00%[157]. Industry Position and Market Trends - The company operates in the specialized equipment manufacturing industry, specifically in the sub-sector of other specialized equipment manufacturing[26]. - The intelligent pharmaceutical management equipment manufacturing industry has seen rapid development since the early 2000s, with automation technology being increasingly adopted in hospitals[27]. - The company is positioned to benefit from the increasing demand for intelligent pharmaceutical management systems due to rising drug varieties and quantities in hospitals[29]. - The establishment of intravenous medication preparation centers has created broader development space for intelligent pharmaceutical management[30]. - The Chinese government has implemented policies to enhance the automation and efficiency of pharmaceutical management in hospitals, promoting the adoption of high-tech automated equipment[31]. - The company is expected to leverage the growth in the retail pharmacy sector driven by "Internet + healthcare" policies, which will encourage the transformation and upgrading of retail pharmacies[32]. - The "14th Five-Year Plan" emphasizes the construction of a high-quality and efficient healthcare service system, which aligns with the company's strategic goals[32]. - The company has a market share of 30.20% in the outpatient pharmacy automation sector, ranking first in the industry as of the end of 2018[34]. Research and Development - R&D expenses increased to 9.82 million yuan, reflecting a growth of 57.94% year-on-year, driven by enhanced investment in new product development[52]. - The company has established a comprehensive R&D system and has a team with nearly 20 years of experience in intelligent drug management[45]. - The company is currently developing new products such as hospital logistics robots, automated pharmacies, and automated traditional Chinese medicine dispensing machines[38]. - The company's intelligent pharmacy project enhances drug dispensing efficiency and reduces human error through automated systems[36]. - The intelligent intravenous preparation center project allows for rapid and accurate preparation of intravenous medications, minimizing direct contact with toxic chemicals[37]. Financial Management and Cash Flow - Cash and cash equivalents at the end of the period decreased by 25.56% to ¥416.80 million, accounting for 40.20% of total assets, primarily due to the purchase of financial products[64]. - Trading financial assets increased to ¥100.00 million, representing 9.64% of total assets, mainly from the purchase of wealth management products[64]. - Accounts receivable rose by 6.85% to ¥221.38 million, accounting for 21.35% of total assets, driven by increased sales[64]. - Inventory increased by 59.00% to ¥39.15 million, representing 3.78% of total assets, as a result of increased stocking due to higher sales[64]. - The company reported a net cash flow from investment activities of -162,608,247.43 RMB, a significant increase in outflow compared to -29,931,593.56 RMB last year[163]. - The total cash and cash equivalents at the end of the period were 416,801,959.98 RMB, down from 559,879,717.59 RMB at the beginning of the period[163]. Shareholder Commitments and Governance - The company has committed to a share lock-up period from December 22, 2020, to December 21, 2023, for major shareholders and actual controllers[94]. - The company has ensured compliance with all commitments made during the reporting period, with no delays or failures reported[95]. - The company has outlined a strategy to address competition and related party transactions, ensuring long-term stability[97]. - The company commits to not transferring or entrusting the management of shares held before the issuance for 36 months post-IPO[100]. - The company will publicly apologize and disclose reasons for any failure to meet commitments in designated media[14]. - The company emphasizes compliance with all relevant laws and regulations regarding shareholding changes[101]. Related Party Transactions and Legal Compliance - The company reported a related party transaction with Willach amounting to 13,516,758.60 RMB, which represents 51.99% of the estimated transaction amount of 26 million RMB for 2021[129]. - The company confirmed that there are no undisclosed related party transactions that should be reported according to legal regulations[126]. - The controlling shareholders and actual controllers have committed to avoid any competitive business activities with the company[124]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[127]. - The company has not received any penalties or corrective actions related to violations of laws or regulations during the reporting period[128]. Future Outlook and Strategic Initiatives - The company plans to continue expanding its capital base to support future growth initiatives[171]. - The increase in unallocated profits suggests a focus on reinvestment strategies for future development[173]. - The company is committed to enhancing its financial stability through prudent management of equity and reserves[171]. - The company has plans for market expansion and new product development, focusing on healthcare and technology sectors[143]. - The company is exploring potential mergers and acquisitions to strengthen its market presence and diversify its offerings[143]. - The company has outlined future performance guidance, aiming for a growth rate of approximately 10% in the upcoming fiscal year[143].

Financial Performance - Operating revenue increased by 33.97% to CNY 40,811,846.52 year-on-year[5] - Net profit attributable to shareholders rose by 8.34% to CNY 6,374,142.56[5] - Net profit after deducting non-recurring gains and losses surged by 47.64% to CNY 6,069,539.77[5] - Basic and diluted earnings per share decreased by 16.67% to CNY 0.05[7] - Total revenue for Q1 2021 was CNY 40,811,846.52, representing a 34.2% increase from CNY 30,462,390.90 in Q1 2020[27] - Net profit for Q1 2021 reached CNY 7,378,978.29, a 11.6% increase compared to CNY 6,614,680.73 in Q1 2020[28] - Operating profit for Q1 2021 was CNY 8,554,132.87, up 11.3% from CNY 7,687,190.27 in Q1 2020[28] - Comprehensive income for Q1 2021 totaled CNY 7,378,978.29, an increase from CNY 6,614,680.73 in Q1 2020[29] Cash Flow and Investments - Cash flow from operating activities showed a net outflow of CNY 51,838,262.91, worsening from a net outflow of CNY 44,991,571.69 in the previous year[5] - The company's cash flow from operating activities saw a 135.68% increase year-over-year, totaling ¥1,668,135.15, mainly due to higher interest income[17] - Cash inflow from operating activities in Q1 2021 was CNY 34,314,925.68, an increase of 25.5% compared to CNY 27,304,736.89 in Q1 2020[33] - Cash outflow from investing activities in Q1 2021 totaled CNY 64,800,526.88, significantly higher than CNY 17,178,468.19 in Q1 2020, indicating increased investment activity[34] - The company invested CNY 50,000,000.00 in Q1 2021, indicating a strategic focus on growth and expansion[37] Assets and Liabilities - Total assets decreased by 3.85% to CNY 958,984,906.41 compared to the end of the previous year[5] - Total assets amounted to CNY 997,404,072.75, with non-current assets totaling CNY 175,183,711.05[40] - Current liabilities decreased from ¥117,188,274.83 to ¥71,390,130.20, a reduction of about 39.1%[22] - Total liabilities reached CNY 119,788,274.83, with non-current liabilities at CNY 2,600,000.00[41] - The company reported a total current asset of ¥479,850,895.68, down from ¥512,239,855.07, a decrease of approximately 6.3%[25] Shareholder Information - The total number of shareholders reached 15,748 at the end of the reporting period[10] - The largest shareholder, Dai Jianwei, holds 42.00% of the shares[10] Research and Development - Research and development expenses surged by 51.18% year-over-year to ¥4,236,733.51, reflecting the company's increased investment in R&D projects[16] - R&D expenses increased to CNY 4,236,733.51 in Q1 2021, up 51.1% from CNY 2,802,363.50 in Q1 2020[27] Inventory and Costs - The cost of goods sold rose by 32.06% year-over-year to ¥19,154,037.80, in line with the revenue growth[15] - Inventory increased by 32.87% compared to the end of 2020, amounting to ¥32,718,943.17, driven by higher raw material purchases due to sales growth[13] - Total operating costs for Q1 2021 were CNY 31,247,677.80, up 30.2% from CNY 23,979,119.59 in Q1 2020[27] - Sales expenses rose by 34.07% year-over-year to ¥3,558,468.23, correlating with the increase in revenue[16] Other Financial Metrics - The weighted average return on equity decreased by 1.28 percentage points to 0.78%[5] - The company's tax payable decreased by 98.67% compared to the end of 2020, amounting to ¥374,080.21, due to the payment of fourth-quarter income tax[12] - The company's minority interest profit increased by 37.37% year-over-year, reaching ¥1,004,835.73, driven by higher profits from subsidiaries[18] - The company's cash and cash equivalents decreased to ¥438,938,640.02 from ¥559,879,717.59 at the end of 2020[21]

Financial Performance - The net profit attributable to the parent company's shareholders for 2020 was ¥95,739,268.21, with a total distributable profit of ¥303,280,521.11 as of December 31, 2020[4]. - The proposed cash dividend distribution is ¥2.15 per 10 shares (including tax), totaling ¥29,240,000.00 (including tax), which represents 30.54% of the net profit attributable to the parent company[4]. - The company's operating revenue for 2020 was CNY 286.81 million, a decrease of 4.47% compared to CNY 300.24 million in 2019[21]. - Net profit attributable to shareholders increased by 4.17% to CNY 95.74 million in 2020 from CNY 91.90 million in 2019[21]. - The company's total assets reached CNY 997.40 million at the end of 2020, representing a 106.76% increase from CNY 482.40 million at the end of 2019[22]. - Basic earnings per share for 2020 were CNY 0.94, up 4.44% from CNY 0.90 in 2019[23]. - The weighted average return on equity decreased to 29.01% in 2020 from 38.03% in 2019, a decline of 9.02 percentage points[23]. - The net cash flow from operating activities was CNY 71.78 million, down 5.60% from CNY 76.03 million in 2019[21]. - The company's net assets attributable to shareholders increased by 182.70% to CNY 813.15 million in 2020 from CNY 287.63 million in 2019[22]. - The company reported a net profit of CNY 36.70 million in Q4 2020, showing strong performance in the last quarter[25]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[3]. - The board of directors has thoroughly reviewed the timing and conditions for profit distribution, ensuring compliance with regulations[5]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[8]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[6]. - The company is committed to maintaining the accuracy and completeness of the annual report, with all directors present at the board meeting[7]. Market and Industry Trends - The company focuses on intelligent drug management for the medical service and pharmaceutical distribution industries, aiming to enhance efficiency and service quality while reducing direct contact with hazardous drugs[30]. - The smart pharmacy project integrates hardware and software to automate drug storage, dispensing, and management, improving efficiency and reducing human error[32]. - The intelligent intravenous preparation center project utilizes various automated devices to ensure rapid and accurate drug preparation, minimizing direct contact with toxic chemicals[33]. - The intelligent drug and consumable management project employs IoT technology for secure storage and intelligent distribution of drugs and consumables[34]. - The global intelligent drug management equipment manufacturing industry has seen significant growth, with automation adoption rates in developed countries reaching approximately 30% by 2013[40]. - In the U.S., 97% of hospitals were equipped with automated dispensing devices by the end of 2014, indicating a strong trend towards automation in healthcare[40]. - In China, the demand for intelligent drug management systems has increased due to rising drug varieties and quantities, as well as higher service quality standards[41]. - The traditional drug management model is becoming inadequate, making intelligent drug management essential for hospitals to reduce operational costs and improve service quality[42]. Research and Development - The company has a well-established R&D system with nearly 20 years of experience in intelligent drug management, enhancing its technical innovation and new product development capabilities[50]. - The company has obtained a total of 111 authorized patents, including 6 invention patents and 67 software copyrights, enhancing its core competitiveness[60]. - The company is enhancing its R&D capabilities by collaborating with multiple technology firms to introduce advanced technologies into new product development[60]. - The total R&D expenditure for the period was ¥16,344,430.17, accounting for 5.70% of the operating revenue[78]. - The number of R&D personnel is 65, representing 19.06% of the total workforce[78]. Shareholder and Governance - The company has a history of consistent profit distribution, with previous years showing no cash dividends or stock dividends[116]. - The management team is committed to transparency and adherence to regulatory requirements regarding shareholding[121]. - The company reported a commitment from major shareholders to not transfer or delegate management of their shares for 36 months post-IPO[121]. - The controlling shareholder, Sun Dong, committed to not transferring or entrusting the management of shares held indirectly for 36 months post-listing[122]. - The company is focused on maintaining shareholder value through strict share transfer commitments[121]. - The company has established a priority right for the acquisition of any competing enterprises controlled by the shareholders if the company expands its business scope[145]. - The company has confirmed that there are no undisclosed related party transactions with its controlling shareholders[148]. - The company has retained Lixin Accounting Firm for its 2020 financial audit, with an audit fee of 700,000 RMB[151]. Social Responsibility - The company actively donated equipment to high-risk medical institutions during the pandemic, demonstrating its social responsibility[60]. - The company was awarded the "2020 Listed Company Social Responsibility Award" at the 10th China Public Welfare Festival[163]. - The company donated a self-service dispensing machine to Shenzhen Third People's Hospital to reduce patient wait times and infection risks[163]. - The company also donated an intelligent drug management cabinet to Jinan Central Hospital, aimed at reducing the workload of medical staff in isolation wards[163]. Risks and Challenges - The reliance on Willach for core components of the H series automated dispensing machine poses a significant risk to the company's operations[98]. - The COVID-19 pandemic has delayed the implementation of automated drug management projects, potentially impacting future performance[107]. - The company faces risks related to trade policy changes in Germany, which could affect the cost of imported raw materials[109]. - The production and sales of automatic dispensing machines are subject to restrictions based on joint venture agreements, which may limit market expansion[110]. - The accounts receivable balance as of 2020 was RMB 207.19 million, with a book value of RMB 234.15 million, indicating potential liquidity risks[104]. Future Strategies - The company plans to enhance R&D investment and talent development to maintain its leading position in the intelligent drug management sector[90]. - The market development strategy includes expanding into the retail pharmacy sector, which is currently experiencing lower automation levels compared to healthcare institutions[93]. - The company aims to improve its marketing and customer service network to penetrate deeper into the market, especially in less developed regions[92]. - The company is exploring opportunities for mergers and acquisitions to strengthen its competitive edge[120].